GlaxoSmithKline plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||
|
a) |
Name |
Ms E Walmsley |
||||||||||
|
b) |
Position/status |
Chief Executive Officer |
||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. |
||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
1881.000
£ 16.3240
|
||||||||||
|
e) |
Date of the transaction |
2019-07-12 |
||||||||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||
|
a) |
Name |
Mr R G Connor |
||||||||||
|
b) |
Position/status |
President, Global Vaccines |
||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. |
||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
564.000
£ 16.3240
|
||||||||||
|
e) |
Date of the transaction |
2019-07-12 |
||||||||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||
|
a) |
Name |
Mr N Hirons |
||||||||||
|
b) |
Position/status |
SVP, Global Ethics & Compliance |
||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. |
||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
297.000
£ 16.3240
|
||||||||||
|
e) |
Date of the transaction |
2019-07-12 |
||||||||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||
|
a) |
Name |
Mr L Miels |
||||||||
|
b) |
Position/status |
President, Global Pharmaceuticals |
||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. |
||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||
|
d) |
Aggregated information
Aggregated volume Price |
350.000
£ 16.3240
|
||||||||
|
e) |
Date of the transaction |
2019-07-12 |
||||||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||||
|
a) |
Name |
Mr D Redfern |
||||||||||
|
b) |
Position/status |
Chief Strategy Officer |
||||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. |
||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||
|
d) |
Aggregated information
Aggregated volume Price |
503.000
£ 16.3240 |
||||||||||
|
e) |
Date of the transaction |
2019-07-12 |
||||||||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Mr R Simard |
||||
|
b) |
Position/status |
President, Pharmaceuticals Supply Chain |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
N/A
|
||||
|
e) |
Date of the transaction |
2019-07-12 |
||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||
|
a) |
Name |
Mr P C Thomson |
||||||||
|
b) |
Position/status |
President, Global Affairs |
||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. |
||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||
|
d) |
Aggregated information
Aggregated volume Price |
289.000
£ 16.3240
|
||||||||
|
e) |
Date of the transaction |
2019-07-12 |
||||||||
|
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||||
|
a) |
Name |
Mr B McNamara |
||||||||
|
b) |
Position/status |
CEO, GSK Consumer Healthcare |
||||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
||||||||
|
b) |
Nature of the transaction |
Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 11 July 2019 on ADS held in the Company's Deferred Annual Bonus Plan. |
||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||
|
d) |
Aggregated information
Aggregated volume Price |
226.000
$ 40.9300 |
||||||||
|
e) |
Date of the transaction |
2019-07-12 |
||||||||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
||||||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Dr H Barron |
||||
|
b) |
Position/status |
Chief Scientific Officer and President, R&D |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
||||
|
b) |
Nature of the transaction |
Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 11 July 2019 on ADS held in the Company's Deferred Annual Bonus Plan. |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
n/a
|
||||
|
e) |
Date of the transaction |
2019-07-12 |
||||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Mr J Ford |
||||
|
b) |
Position/status |
SVP and General Counsel |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
||||
|
b) |
Nature of the transaction |
Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 11 July 2019 on ADS held in the Company's Deferred Annual Bonus Plan.
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
n/a
|
||||
|
e) |
Date of the transaction |
2019-07-12 |
||||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||||
|
a) |
Name |
Ms K Terrell |
||||||
|
b) |
Position/status |
Chief Digital & Technology Officer |
||||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a) |
Name |
GlaxoSmithKline plc |
||||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
||||||
|
b) |
Nature of the transaction |
Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 11 July 2019 on ADS held in the Company's Deferred Annual Bonus Plan. |
||||||
|
c) |
Price(s) and volume(s) |
|
||||||
|
d) |
Aggregated information
Aggregated volume Price |
116.000
$ 40.9300
|
||||||
|
e) |
Date of the transaction |
2019-07-12 |
||||||
|
f) |
Place of the transaction
|
New York Stock Exchange (XNYS) |
||||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
